FedEx Express, a subsidiary of NYSE-listed FedEx, unveiled its FedEx Life Science Center in Mumbai, setting a benchmark in the clinical trial supply chain in India and globally.
The new capability will meet and support the clinical trial storage and logistics requirements of healthcare customers both within the India market and those shipping to India from around the world, says an official release. “The facility has ensured compliance with quality and regulatory requirements of the healthcare industry.”
Key features of the new centre include:
*Covering all three temperature-controlled zones
*Controlled ambient (15°C to 25°C)
*Refrigerated (2°C to 8°C)
*Frozen -20°C and Deep Frozen -80°C
*24/7 monitoring and alarms for immediate response and intervention
*Destruction services for returned investigational medicinal products (IMPs)
*Equipped with document storage and a secure archival facility with fire-safe walls
*Quality management system compliance with Good Clinical Practice (GCP) and Good Distribution Practice (GDP); and
*Use of gel pack and dry ice for secure packing and replenishment
Nitin Navneet Tatiwala, Vice President, Marketing, FedEx Express Middle East, India Subcontinent & Africa says: “With FedEx having deep expertise in handling critical clinical trial shipments, the launch of FedEx Life Science Center (LSC) will act as a one-stop shop for all clinical trial storage and distribution requirements of healthcare customers in India. The new centre is in addition to FedEx’s current LSCs in Japan, South Korea, Singapore, the USA, and the Netherlands – making it a global network of storage and distribution depots to support our healthcare and pharmaceutical customers.”
Customers can leverage FedEx Customised Freight (FCF) for the transportation of critical pharmaceutical freight shipments and choose FedEx Priority Alert Plus for the monitoring of time-sensitive shipments, the release added.
